Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea Pulse Therapy vs Imatinib in Chronic Myeloid Leukemia
NCT03515018Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of hydroxyurea in chronic myeloid leukemia (CML) (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: Time of WBC decreased by 10%, 20%, 30%, 50% at 2 years. Status: unknown.
02
Drugs
hydroxyurea
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03515018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515018.